<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01184079</url>
  </required_header>
  <id_info>
    <org_study_id>IISP#38206</org_study_id>
    <secondary_id>PRO10070407</secondary_id>
    <secondary_id>I#0021806</secondary_id>
    <nct_id>NCT01184079</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University Setting</brief_title>
  <official_title>Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a randomized, open label trial of the immunogenicity of HPV vaccine
      among males 18-24 years old, comparing an on-time administration of the third dose with
      delayed administration of the third dose. All participants would receive the first and second
      doses according to schedule. They would be randomized to either Dose 3 at 6 months or Dose 3
      at 12 months.

      Hypothesis: The Geometric mean titers in the 12 month test group (T) are non-inferior to the
      usual timing control group (C):

      H0: δ ≤ −δ0 versus H1: δ &gt; −δ0 where δ = log (GMTT )− log (GMTC) and δ0 is the pre-specified
      non-inferiority margin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Specific Aims and Overview: The investigators propose a randomized, open label trial of
      HPV vaccine among males 18-24 years old, comparing an on-time administration of the third
      dose with delayed administration of the third dose. All participants would receive the first
      and second doses according to schedule. They would be randomized to either Dose 3 at 6 months
      or Dose 3 at 12 months.

      Blood would be drawn for titers at twice from all participants: pre-dose 1 and one month post
      Dose 3.

      No cytology studies or DNA studies will be conducted.

      1.1 Aims:

        1. Determine if delay in the third dose is immunologically non-inferior to the standard
           administration schedule (1 month post-dose 3).

        2. Determine the side effect profile of a delayed third dose, in comparison to the standard
           schedule.

        3. Determine the preference and compliance of the men for the timing of the third dose.

      1.2 Hypothesis for non- inferiority:

      The GMTs in the test group (T) are non-inferior to the usual timing control group (C):

      H0: δ ≤ −δ0 versus H1: δ &gt; −δ0 where δ = log (GMTT )− log (GMTC) and δ0 is the pre-specified
      non-inferiority margin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity After Dose 3</measure>
    <time_frame>1 month after dose 3 (e.g., month 7 if third dose at 6months or month 13 if third dose at 12 months)</time_frame>
    <description>Geometric mean titer (GMT) and 95% confidence intervals around titer 1 month after dose 3 in per protocol population, comparing the two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance With 3rd Dose</measure>
    <time_frame>at 3rd dose (i.e., at month 6 or month 12, depending on arm)</time_frame>
    <description>Determine the compliance of the men for the timing of the third dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Profile</measure>
    <time_frame>1 week after vaccination</time_frame>
    <description>Total proportion of side effects reported after any dose, compared by arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Quadrivalent HPV Vaccine</condition>
  <condition>Human Papillomavirus Vaccine</condition>
  <arm_group>
    <arm_group_label>12 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of 3rd dose at 12 months quadrivalent human papillomavirus vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 month</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of 3rd dose at 6 months quadrivalent human papillomavirus vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>quadrivalent human papillomavirus vaccine</intervention_name>
    <description>0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months</description>
    <arm_group_label>12 months</arm_group_label>
    <other_name>Gardasil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>quadrivalent human papillomavirus vaccine</intervention_name>
    <description>0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months</description>
    <arm_group_label>6 month</arm_group_label>
    <other_name>Gardasil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males age 18-26

        Exclusion Criteria:

          -  Hospitalization within the past year

          -  Previous HPV vaccination

             &gt;/=5 sexual partners (i.e., insertive intercourse) No other drug studies within 30
             days of proposed HPV vaccination

          -  History of genital warts

          -  Immunosuppression

          -  Other vaccines within 8 days of proposed HPV vaccination

          -  Hypersensitivity to yeast or HPV vaccine components

          -  Known autoimmune disorders

          -  Receipt of immunoglobulins or blood product within 90 days of enrollment (may defer
             until 90 days completed)

          -  Serious Adverse Reaction to HPV vaccine
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard K Zimmerman, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zimmerman RK, Nowalk MP, Lin CJ, Fox DE, Ko FS, Wettick E, Cost G, Hand L, Hayes J, Michaels M. Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women. J Womens Health (Larchmt). 2010 Aug;19(8):1441-7. doi: 10.1089/jwh.2009.1753.</citation>
    <PMID>20629576</PMID>
  </reference>
  <results_reference>
    <citation>Lin CJ, Zimmerman RK, Nowalk MP, Huang HH, Raviotta JM. Randomized controlled trial of two dosing schedules for human papillomavirus vaccination among college age males. Vaccine. 2014 Feb 3;32(6):693-9. doi: 10.1016/j.vaccine.2013.11.098. Epub 2013 Dec 14.</citation>
    <PMID>24342252</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2010</study_first_submitted>
  <study_first_submitted_qc>August 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2010</study_first_posted>
  <results_first_submitted>November 4, 2013</results_first_submitted>
  <results_first_submitted_qc>January 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 26, 2014</results_first_posted>
  <last_update_submitted>February 26, 2014</last_update_submitted>
  <last_update_submitted_qc>February 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Richard Zimmerman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>human papillomavirus vaccine L1, type 6,11,16,18</keyword>
  <keyword>HPV Vaccines</keyword>
  <keyword>HPV L1 vaccine, quadrivalent 6,11,16,18</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From October 2010 through May 2011, college age men, ages 18-25 years, were recruited using a variety of strategies including fliers, class announcements, recommendations by university health centers, emails to campus organizations, bus and campus newspaper advertisements, and targeted Facebook® advertisements.</recruitment_details>
      <pre_assignment_details>Exclusion criteria were: &gt;4 lifetime sexual partners, health problems that would interfere with the immune response or ability to complete the study, a hospitalization during the past year, hypersensitivity to yeast or HPV vaccine components, inability to complete appointments, received HPV vaccine or immunosuppressive medications.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>12 Month Administration</title>
          <description>Administration of 3rd dose at 12 months
quadrivalent human papillomavirus vaccine : 0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months</description>
        </group>
        <group group_id="P2">
          <title>6 Month Administration</title>
          <description>3rd dose administration at 6 months
quadrivalent human papillomavirus vaccine : 0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Final Blood Draw</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>12 Month Administration</title>
          <description>Administration of 3rd dose at 12 months
quadrivalent human papillomavirus vaccine : 0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months</description>
        </group>
        <group group_id="B2">
          <title>6 Month Administration</title>
          <description>3rd dose administration at 6 months
quadrivalent human papillomavirus vaccine : 0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
            <count group_id="B2" value="109"/>
            <count group_id="B3" value="220"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.3" spread="2.3"/>
                    <measurement group_id="B2" value="21.4" spread="2.2"/>
                    <measurement group_id="B3" value="21.3" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity After Dose 3</title>
        <description>Geometric mean titer (GMT) and 95% confidence intervals around titer 1 month after dose 3 in per protocol population, comparing the two groups.</description>
        <time_frame>1 month after dose 3 (e.g., month 7 if third dose at 6months or month 13 if third dose at 12 months)</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>12 Month Administration</title>
            <description>Administration of 3rd dose at 12 months
quadrivalent human papillomavirus vaccine : 0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months</description>
          </group>
          <group group_id="O2">
            <title>6 Month Administration</title>
            <description>3rd dose administration at 6 months
quadrivalent human papillomavirus vaccine : 0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity After Dose 3</title>
          <description>Geometric mean titer (GMT) and 95% confidence intervals around titer 1 month after dose 3 in per protocol population, comparing the two groups.</description>
          <population>Intention-to-treat</population>
          <units>mM units/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1063" lower_limit="793" upper_limit="1312"/>
                    <measurement group_id="O2" value="794" lower_limit="565" upper_limit="1009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1961" lower_limit="1480" upper_limit="2403"/>
                    <measurement group_id="O2" value="1043" lower_limit="689" upper_limit="1382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6186" lower_limit="4947" upper_limit="7315"/>
                    <measurement group_id="O2" value="4555" lower_limit="3243" upper_limit="5788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1049" lower_limit="728" upper_limit="1350"/>
                    <measurement group_id="O2" value="709" lower_limit="338" upper_limit="1103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary endpoint would demonstrate noninferiority if the upper bound of the 95% two-sided confidence interval (CI) of the ratio of GMT for Standard schedule group divided by that of Alternate schedule group is &lt;1.5.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size: (1 + 1/u)(Zα + Zβ)2 σ2 /[log (RGMT) −δ0] u= ratio of the size of the Standard schedule to Alternate schedule groups (u =1, for equal size groups); one-sided alpha (0.025)/4 for multiplicity of serotypes. Average log-transformed and geometric mean titers (GMTs) with a two-sided 95% confidence interval of the ratio of the GMTs were used.
Non-inferiority is determined if upper bound GMT ratio of standard group to alternate group &lt; 1.5.</non_inferiority_desc>
            <param_type>largest upper bound GMT ratio</param_type>
            <param_value>0.82</param_value>
            <estimate_desc>Non-inferiority is determined if upper bound GMT ratio of standard 6 month group to alternate 12 month group &lt; 1.5.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compliance With 3rd Dose</title>
        <description>Determine the compliance of the men for the timing of the third dose.</description>
        <time_frame>at 3rd dose (i.e., at month 6 or month 12, depending on arm)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>12 Month Administration</title>
            <description>Administration of 3rd dose at 12 months
quadrivalent human papillomavirus vaccine : 0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months</description>
          </group>
          <group group_id="O2">
            <title>6 Month Administration</title>
            <description>3rd dose administration at 6 months
quadrivalent human papillomavirus vaccine : 0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance With 3rd Dose</title>
          <description>Determine the compliance of the men for the timing of the third dose.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Profile</title>
        <description>Total proportion of side effects reported after any dose, compared by arm.</description>
        <time_frame>1 week after vaccination</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Group With Administration of 3rd Dose at 12 Months</title>
            <description>Group with administration of 3rd dose at 12 months
quadrivalent human papillomavirus vaccine : 0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months</description>
          </group>
          <group group_id="O2">
            <title>Group With Administration of 3rd Dose at 6 Months</title>
            <description>Group with administration of 3rd dose at 6 months
quadrivalent human papillomavirus vaccine : 0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Profile</title>
          <description>Total proportion of side effects reported after any dose, compared by arm.</description>
          <population>Intention-to-treat</population>
          <units>percentage of doses with side effects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9"/>
                    <measurement group_id="O2" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>null hypothsesis: no difference in proportion of side effects reported between groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>12 Month Administration</title>
          <description>Administration of 3rd dose at 12 months
quadrivalent human papillomavirus vaccine : 0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months</description>
        </group>
        <group group_id="E2">
          <title>6 Month Administration</title>
          <description>3rd dose administration at 6 months
quadrivalent human papillomavirus vaccine : 0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Drop-out rates higher in the Alternate group; however, sample size was met for all HPV types. The effect of the Alternate dosing schedule on long-term clinical outcomes is unknown. One syncopal episode related to phlebotomy prior to vaccination.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chyongchiou Jeng Lin, PhD</name_or_title>
      <organization>University of Pittsburgh Department of Family Medicine</organization>
      <phone>412/383-2360</phone>
      <email>cjlin@pitt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

